Cat. No：GM-C09520
Product：H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Cat. No：GM-C09520
Product：H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Cell Growth Medium： RPMI1640 +10% FBS +0.75ug/ml Puromycin+3.5ug/ml Blastincidin +1% P.S
Cell Freezing Medium： FBS+10% DMSO
Assay Buffer：99% RPMI1640 +1% FBS +1% P.S
CD40 is a member of the tumor necrosis factor (TNF) receptor family, also known as TNFRSF5. CD40 is expressed in antigen-presenting cells (APCs) such as B cells, dendritic cells (DCs), monocytes, as well as many non-immune cells and various types of cancer cells. CD40L is the natural trimeric ligand of CD40, expressed on multiple cell types. The CD40-CD40L pair is a co-stimulatory molecule, where upon interaction on cell surfaces, CD40 recruits TNF receptor-associated factors (TRAF) in the cytoplasm to promote intracellular signaling, activating different signaling pathways involved in the body's immune response. Activated CD40 monoclonal antibodies have been shown to activate APCs and promote anti-tumor T cell responses, playing a significant role in cancer therapy.
H_CD40(TNFRSF5) Reporter Jurkat Cell Line is a reporter gene cell line. When a CD40 agonist binds to the CD40 receptor, downstream reporter genes are activated, subsequently activating the expression of luciferase. Luciferase readings reflect the activation effect of the signaling pathway, thus it can be used for evaluating the in vitro effects of CD40-related drugs.
Liu F, Yang Y, Gong W, et al. Tumor antigen-dependent cd40 agonists antibodies: U.S. Patent Application 18/582,571[P]. 2024-7-25.
Cat. No：GM-C09520
Product：H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Cell Growth Medium： RPMI1640 +10% FBS +0.75ug/ml Puromycin+3.5ug/ml Blastincidin +1% P.S
Cell Freezing Medium： FBS+10% DMSO
Assay Buffer：99% RPMI1640 +1% FBS +1% P.S
CD40 is a member of the tumor necrosis factor (TNF) receptor family, also known as TNFRSF5. CD40 is expressed in antigen-presenting cells (APCs) such as B cells, dendritic cells (DCs), monocytes, as well as many non-immune cells and various types of cancer cells. CD40L is the natural trimeric ligand of CD40, expressed on multiple cell types. The CD40-CD40L pair is a co-stimulatory molecule, where upon interaction on cell surfaces, CD40 recruits TNF receptor-associated factors (TRAF) in the cytoplasm to promote intracellular signaling, activating different signaling pathways involved in the body's immune response. Activated CD40 monoclonal antibodies have been shown to activate APCs and promote anti-tumor T cell responses, playing a significant role in cancer therapy.
H_CD40(TNFRSF5) Reporter Jurkat Cell Line is a reporter gene cell line. When a CD40 agonist binds to the CD40 receptor, downstream reporter genes are activated, subsequently activating the expression of luciferase. Luciferase readings reflect the activation effect of the signaling pathway, thus it can be used for evaluating the in vitro effects of CD40-related drugs.
Liu F, Yang Y, Gong W, et al. Tumor antigen-dependent cd40 agonists antibodies: U.S. Patent Application 18/582,571[P]. 2024-7-25.
